
Quick Take
Translate Bio (TBIO) intends to sell shares of its common stock to raise $100 million from a U.S. IPO, according to an S-1/A registration statement.
The firm is advancing a pipeline of mRNA-based treatment candidates to restore protein function in patients with cystic fibrosis and OTC deficiency.
The TBIO IPO has the support of existing investors but the proposed valuation is pricey.
Prospective investors would likely need to hold the stock for a considerable time before seeing a meaningful upside catalyst.

